Skip to navigation menu Skip to content
High Priority Alert

We are experiencing extremely high demand in our Emergency Department. Learn more.

High Priority Alert

Masking and Visitation Changes: Due to high rates of respiratory illnesses in our community, we’ve made changes to our masking and visitation guidelines. Learn more.

IL1RAP CARs and CAR T cells

Novel CARs and CAR T cells targeting IL1RAP expressing cancers

Download summary

Technology overview

Interleukin-1 receptor accessory protein (IL1RAP) is a cell surface molecule that is overexpressed in hematologic malignancies and in certain solid tumors. Notably, IL1RAP is over expressed in acute myeloid leukemia, chronic myeloid leukemia and in pediatric solid tumors including Ewing’s sarcoma. IL1RAP is also expressed in subsets of adult carcinomas including pancreatic cancer, thyroid cancer, endometrial cancer, lung cancer, renal cancer, and liver cancer. Antibody and CAR T-cell-based therapeutics targeting IL1RAP have been validated in preclinical studies and clinical trials in adults are forthcoming.

Dr. Rimas Orentas has developed novel CARs that specifically target IL1RAP. T cells expressing the IL1RAP CARs successfully targeted and lysed Ewing’s sarcoma cell lines in vitro. These CARs are novel compositions of matter that can be incorporated into other therapeutic immune effector cells including NK cells.


  • CAR T-cell therapy for IL1RAP-expressing cancers
  • CAR T-cell therapy for solid tumors
  • IL1RAP CAR can be used with different immune effector cells


  • Novel IL1RAP specific CAR

Market overview

The global CAR T-cell therapy market was valued at USD $467 million in 2018 and is expected to reach USD $2.9 billion by 2023, growing at a CAGR of 44.1%. Ewing’s sarcoma is the second most common primary bone tumor in children and accounts for approximately 2% of all childhood cancer diagnoses. Acute myeloid leukemia is one of the most common types of leukemia in adults, and chronic myeloid leukemia accounts for 15% of all new cases of leukemia.


Exclusive license

Technology type


Cell therapy

Technology status

Preclinical in vitro

Patent status

Patent pending


Rimas Orentas, PhD

Learn more

To learn more about this technology, please email Kamya Rajaram.

By clicking “Accept All Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in marketing efforts. For more information, see Website Privacy.

Accept All Cookies